Bibliography for PC929: Applied Pharmacology and Therapeutics in Diabetes Care BETA

ABIOLA, D., SATHYAPALAN, T. and HEPBURN, D. (2016a) ‘Management of type 1 and type 2 diabetes requiring insulin’, Prescriber [Preprint]. Available at: http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/.

ABIOLA, D., SATHYAPALAN, T. and HEPBURN, D. (2016b) ‘Management of type 1 and type 2 diabetes requiring insulin’, Prescriber [Preprint]. Available at: http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/.

Bangstad, H.-J. et al. (2009) ‘Insulin treatment in children and adolescents with diabetes’, Pediatric Diabetes, 10(6), pp. 82–99. Available at: https://doi.org/10.1111/j.1399-5448.2009.00578.x.

Caverly, T.J. et al. (2015) ‘Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia’, JAMA Internal Medicine [Preprint]. Available at: https://doi.org/10.1001/jamainternmed.2015.5950.

Chen, L. et al. (2015) ‘Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis’, Metabolism, 64(2), pp. 338–347. Available at: http://www.metabolismjournal.com/article/S0026-0495(14)00312-6/fulltext.

Complications of Diabetes Mellitus | InTechOpen (no date). Available at: https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus.

Crowley, M.J. et al. (2017) ‘Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease’, Annals of Internal Medicine, 166(3). Available at: https://doi.org/10.7326/M16-1901.

Dauriz, M. et al. (2017) ‘Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry’, Diabetes Care, 40(5), pp. 671–678. Available at: https://doi.org/10.2337/dc16-2016.

‘Diabetes Care: 40 (Supplement 1)’ (2017) Diabetes Care, 40(Supplement 1). Available at: https://0-care-diabetesjournals-org.pugwash.lib.warwick.ac.uk/content/40/Supplement_1.

‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’ (2008) New England Journal of Medicine, 358(24), pp. 2545–2559. Available at: https://doi.org/10.1056/NEJMoa0802743.

‘Effects of Liraglutide on Glycemic Control :Cleveland Clinic Journal of Medicine’ (2015). Available at: http://www.mdedge.com/ccjm/clinical-edge/summary/obesity/effects-liraglutide-glycemic-control.

Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at http://www.go.warwick.ac.uk/values-basedpractice (no date). Available at: http://valuesbasedpractice.org/.

Ettehad, D. et al. (2015) ‘Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis’, The Lancet [Preprint]. Available at: https://doi.org/10.1016/S0140-6736(15)01225-8.

Fadini, G.P., Bonora, B.M. and Avogaro, A. (2017) ‘SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System’, Diabetologia, 60(8), pp. 1385–1389. Available at: https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4301-8.

Filippatos, T.D., Tsimihodimos, V. and Elisaf, M.S. (2016a) ‘Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors’, Expert Opinion on Pharmacotherapy, 17(12), pp. 1581–1583. Available at: http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073.

Filippatos, T.D., Tsimihodimos, V. and Elisaf, M.S. (2016b) ‘Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors’, Expert Opinion on Pharmacotherapy, 17(12), pp. 1581–1583. Available at: http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073.

Fralick, M., Schneeweiss, S. and Patorno, E. (2017) ‘Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor’, New England Journal of Medicine, 376(23), pp. 2300–2302. Available at: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMc1701990.

Gæde, P. et al. (2008) ‘Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes’, New England Journal of Medicine, 358(6), pp. 580–591. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223923658?accountid=14888.

Gæde, P. et al. (2016) ‘Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial’, Diabetologia, 59(11), pp. 2298–2307. Available at: https://doi.org/10.1007/s00125-016-4065-6.

Green, J.B. et al. (2015) ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 373(3), pp. 232–242. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1696912909?accountid=14888.

Hine, J. et al. (2015) ‘SGLT inhibition and euglycaemic diabetic ketoacidosis’, The Lancet Diabetes & Endocrinology, 3(7), pp. 503–504. Available at: http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858715002260?via%3Dihub.

Inzucchi, S.E. et al. (2015) ‘SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials’, Diabetes and Vascular Disease Research, 12(2), pp. 90–100. Available at: https://doi.org/10.1177/1479164114559852.

Ismail, K., Winkley, K. and Rabe-Hesketh, S. (2004) ‘Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes’, The Lancet, 363(9421), pp. 1589–1597. Available at: https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673604162028.

Kosiborod, M. et al. (2017) ‘Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective’, Circulation, 136(3), pp. 249–259. Available at: https://0-www-ncbi-nlm-nih-gov.pugwash.lib.warwick.ac.uk/pubmed/28522450.

Lipska, K.J. et al. (2016) ‘Polypharmacy in the Aging Patient’, JAMA, 315(10). Available at: https://doi.org/10.1001/jama.2016.0299.

Marso, S.P. et al. (2016a) ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, 375(19), pp. 1834–1844. Available at: https://doi.org/10.1056/NEJMoa1607141.

Marso, S.P. et al. (2016b) ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, 375(19), pp. 1834–1844. Available at: https://doi.org/10.1056/NEJMoa1607141.

Marso, S.P. et al. (2017) ‘Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes’, New England Journal of Medicine [Preprint]. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1931756550?accountid=14888.

Maruthur, N.M. et al. (2016) ‘Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes’, Annals of Internal Medicine, 164(11). Available at: https://doi.org/10.7326/M15-2650.

Nauck, M.A. (2013) ‘A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks’, Diabetes Care, 36(7), pp. 2126–2132. Available at: https://doi.org/10.2337/dc12-2504.

Neal, B. et al. (2017) ‘Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes’, New England Journal of Medicine, (377), pp. 644–657. Available at: http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1611925#t=article.

NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at https://www.evidence.nhs.uk/ (no date). Available at: https://www.evidence.nhs.uk/.

Paul, S.K. et al. (2015) ‘Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes’, Cardiovascular Diabetology, 14(1). Available at: https://doi.org/10.1186/s12933-015-0260-x.

‘Pediatric Diabetes’ (no date), 15(S20). Available at: http://onlinelibrary.wiley.com/doi/10.1111/pedi.2014.15.issue-S20/issuetoc.

Pfeffer, M.A. et al. (2015) ‘Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome’, New England Journal of Medicine, 373(23), pp. 2247–2257. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/2119957013/EA851E49618490DPQ/1?accountid=14888.

Pieber, T.R. et al. (2018) ‘DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality’, Diabetologia, 61(1), pp. 58–65. Available at: https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4422-0.

Rang, H. (2012) ‘Pharmacokinetics’, in Rang & Dale’s pharmacology. 7th ed. Edinburgh: Elsevier/Churchill Livingstone, pp. 123–131. Available at: https://contentstore.cla.co.uk/secure/link?id=1d4bfbd8-c343-e611-80bd-0cc47a6bddeb.

Scheen, A.J. (2016) ‘SGLT2 Inhibitors: Benefit/Risk Balance’, Current Diabetes Reports, 16(10). Available at: https://doi.org/10.1007/s11892-016-0789-4.

Scirica, B.M. et al. (2013a) ‘Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus’, New England Journal of Medicine, 369(14), pp. 1317–1326. Available at: https://doi.org/10.1056/NEJMoa1307684.

Scirica, B.M. et al. (2013b) ‘Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus’, New England Journal of Medicine, 369(14), pp. 1317–1326. Available at: https://0-www-nejm-org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684.

Sinclair, A.J. et al. (2016) ‘Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis’, Journal of the American Geriatrics Society, 64(3), pp. 543–552. Available at: https://doi.org/10.1111/jgs.14028.

The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) ‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’, New England Journal of Medicine, 358(24), pp. 2545–2559. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223930983?accountid=14888.

The ADVANCE Collaborative Group (2008) ‘Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, 358(24), pp. 2560–2572. Available at: https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223924651/fulltextPDF/4EC80B054DE144D4PQ/1?accountid=14888.

The American Diabetes Association (no date). Available at: https://www.diabetes.org/.

The Cochrane collaboration at http://www.cochrane.org/ helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.” (no date). Available at: http://www.cochrane.org/.

The commercial but not-for-profit Trip database at http://www.tripdatabase.com claims to be "the internet’s premier source of evidence-based content” (no date). Available at: http://www.tripdatabase.com/.

The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from http://www.casp-uk.net/ (no date). Available at: https://casp-uk.net/casp-tools-checklists/.

The European Association for the Study of Diabetes (EASD) (no date). Available at: http://www.easd.org/.

The George Eliot Diabetes Care Team’s Alphabet Strategy website is at www.abcdiabetes.co.uk (no date). Available at: http://www.abcdiabetes.co.uk/.

The International Diabetes Federation (IDF) is at http://www.idf.org (no date). Available at: http://www.idf.org/.

The Scottish Intercollegiate Guidelines Network website is at http://www.sign.ac.uk (no date). Available at: http://www.sign.ac.uk/.

Vaccaro, O. et al. (2017) ‘Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial’, The Lancet Diabetes & Endocrinology, 5(11), pp. 887–897. Available at: https://doi.org/10.1016/S2213-8587(17)30317-0.

Wanner, C. et al. (2016) ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, 375(4), pp. 323–334. Available at: https://doi.org/10.1056/NEJMoa1515920.

Wu, J.H.Y. et al. (2016) ‘Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis’, The Lancet Diabetes & Endocrinology, 4(5), pp. 411–419. Available at: https://doi.org/10.1016/S2213-8587(16)00052-8.

Young, L.A. et al. (2017) ‘Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings’, JAMA Internal Medicine, 177(7). Available at: https://doi.org/10.1001/jamainternmed.2017.1233.

Zeitler, P. et al. (2014) ‘Type 2 diabetes in child and adolescent’, Pediatric Diabetes, 15, pp. 26–46. Available at: http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/pedi.12179/epdf.

Zinman, B. et al. (2015a) ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’, New England Journal of Medicine, 373(22), pp. 2117–2128. Available at: https://doi.org/10.1056/NEJMoa1504720.

Zinman, B. et al. (2015b) ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’, New England Journal of Medicine, 373(22), pp. 2117–2128. Available at: https://doi.org/10.1056/NEJMoa1504720.

Zinman, B. et al. (2015c) ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’, New England Journal of Medicine, 373(22), pp. 2117–2128. Available at: https://doi.org/10.1056/NEJMoa1504720.